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Copy number variants (CNVs) are major contributors to genetic disorders1. We have
dissected a region on 16p11.2 encompassing 29 genes that confers susceptibility to
neurocognitive defects when deleted or duplicated2,3. Overexpression of each human
transcript in zebrafish embryos identified KCTD13 as the sole message capable of inducing
the microcephaly phenotype associated with the 16p11.2 duplication (dup)2–5, while
suppression of the same locus yielded the macrocephalic phenotype associated with the
16p11.2 deletion (del)5,6, capturing the mirror phenotypes of humans. Analyses of zebrafish
and mouse embryos suggest that microcephaly is caused by decreased proliferation of
neuronal progenitors, with concomitant increase in apoptosis in the developing brain,
whereas macrocephaly arises by increased proliferation and no changes in apoptosis. A role
for KCTD13 dosage changes is consistent with autism in both a recently reported family
with a reduced 16p11.2 deletion and a subject reported here with a complex 16p11.2
rearrangement involving de novo structural alteration of KCTD13. Our data suggest that
KCTD13 is a major driver for the neurodevelopmental phenotypes associated with the
16p11.2 CNV, reinforce the notion that one or a small number of transcripts within a CNV
can underpin clinical phenotypes, and offer an efficient route to identifying dosage sensitive
loci.
Copy number changes have emerged in recent years as a significant source of genetic
variation contributing to the human genetic disease risk1. In addition to genomic disorders
such as Charcot-Marie Tooth, DiGeorge syndrome and others7,8, in which large deletions
and duplications represent penetrant alleles for discrete syndromic phenotypes, recent
advances have highlighted the contribution of such genomic events in a broad range of both
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tcommon and rare traits (DECIPHER Consortium, http://decipher.sanger.co.uk). Systematic
surveys of neurodevelopmental disorders have uncovered an especially high incidence of
both inherited and de novo CNVs that can confer either causality or susceptibility9–12. For
example, deletions in 1q21.1 and 15q13.3 have been associated with schizophrenia (SCZ),
whereas duplications in 15q11-q13 and 7q22-q31 have been associated with autism
spectrum disorder (ASD; see review1).
A 600kb deletion on 16p11.2, encompassing 29 annotated genes, has been associated
significantly and reproducibly with a range of neurocognitive defects, including epilepsy,
autism and ASD2, while the reciprocal duplication has been associated with autism and
SCZ3. In addition, extended phenotypic analyses of patients with such genomic lesions have
revealed strong mirroring co-morbidities: the common 16p11.2 deletion is associated with
pediatric neurodevelopmental disorders including autism, diabetes-independent obesity5 and
macrocephaly6, while the reciprocal duplication is associated with both autism and SCZ,
anorexia and microcephaly2–5. Moreover, a recent post hoc analysis of ASD and SCZ loci
has revealed that such co-morbidities might be causally linked to each other, with
macrocephaly shown to be associated with ASD and microcephaly associated with SCZ13.
A pervasive challenge in the interpretation of CNV discovery is the transition from the
detection of a genomic lesion that can often span large regions encompassing many genes to
the identification of the critical loci whose dosage sensitivity drives the phenotype. For some
disorders, this has been achievable through the discovery of highly penetrant point mutations
at a single locus; for example, mutations in PMP22 are sufficient to cause CMT14, while
mutations in RAI1 cause Smith-Magenis syndrome15. In other instances, gene-specific
genomic alterations such as chromosomal translocations, inversions, or small coding
deletions can narrow the critical region to a single gene (e.g. MBD5 in 2q23.1 microdeletion
syndrome16). Alternatively, systematic functional dissection through mouse mutagenesis has
yielded strong candidates; ablation of Tbx1 recapitulates the cardiac phenotypes of VCSF17,
while knockout of Shank3 captures most of the phenotypes seen in the terminal 22q deletion
that causes Phelan-McDermid syndrome18. However, these approaches are significantly
more challenging for common phenotypes and genetically heterogeneous disorders:
systematic engineering of the mouse genome for each gene in a CNV can be impractical,
while rare mutations involved in complex traits are likely to exhibit both reduced penetrance
and variable expressivity.
Manipulation of zebrafish embryos represents an attractive alternative towards the discovery
of human dosage-sensitive genes, especially when the CNV under investigation has
mirrored anatomical phenotypes that are detectable during early development and that can
thus be assayed by a combination of gene suppression and overexpression experiments19.
Given the association between the 16p11.2 CNV and changes in head size, we hypothesized
that a) systematic overexpression of each of the 29 genes in the common duplication might
yield a defined, reproducible set of transcripts some of which might cause microcephaly; b)
that reciprocal suppression of these genes should yield the macrocephalic phenotype seen in
the 16p11.2del. To test these hypotheses, we first queried the zebrafish genome by
reciprocal BLAST for each of the 29 target genes (Fig. 1a) and identified 24 orthologs
(Suppl. Table 1), with five genes, SPN, QPRT, C16orf54, TMEM219, C16orf92, found only
in placental mammals. In a manner akin to the classic Drosophila misexpression
experiments, we generated capped mRNA for all 29 human genes and injected zebrafish
embryos at the two-cell stage with equimolar pairwise ‘cocktail’ combinations at two
dosages of 25 pg and 50 pg; these commonly used ranges20 were selected because they
represent >0.25–0.5% of total polyA+ mRNA in a zebrafish embryo21 and are thus likely to
achieve significant overexpression above the baseline of any single transcript.
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tOne gene, TAOK2, required reduced mRNA dosage to 10 pg because of toxicity. For the
remaining 28 genes, we observed no lethality or gross morphological defects at either 25 or
50 pg, while random RT-PCR testing of nine injections including KCTD13 showed
persistence of the corresponding human mRNAs up to ~4.25 dpf (Suppl. Fig. 1e). We
therefore developed a surrogate measurement for head size at 4.25–4.5 dpf using objective
measurements, wherein the distance across the convex tips of the eye cups was recorded in
50 embryos/injection, masked to the injection cocktail (Fig. 1b). Only a single
overexpression cocktail containing KCTD13 and CDIPT gave significant changes in head
size (two-tailed t-test, p<0.000001). Subsequent single-mRNA injections for the two genes
indicated that the phenotype was driven exclusively by the overexpression of KCTD13;
injection of KCTD13 at progressive mRNA amounts yielded an increasing percentage of
microcephalic embryos (Fig. 2a, b; Suppl. Fig. 1a). In contrast, the head size of embryos
injected with CDIPT was indistinguishable from those injected with sham control (data not
shown).
To validate the specificity of this phenotype and to ask whether we could also simulate the
macrocephalic phenotype seen usually in 16p11.2del patients4,13, we designed a splice-
blocking morpholino (MO) against the donor site of exon 3 of the sole kctd13 zebrafish
ortholog. Injection of 10ng of MO and RT-PCR testing showed ~70% reduction of kctd13
message at 4.5 dpf (Suppl. Fig. 1c). Strikingly, this injection also yielded a significant
increase in mean head size (p<0.00001; Fig. 2a, b,Suppl. Fig. 1b). This phenotype is specific
to kctd13; a scrambled MO induced no phenotypes, while injection of 10 ng of MO and 50
pg of KCTD13 mRNA rescued both the microcephalic and macrocephalic phenotypes
(Suppl. Fig. 1d). Importantly, measurement of the somitic trunk length of scored embryos
showed no differences in length (or morphology; Suppl. Fig. 2), indicating that the head size
differences are unlikely to be driven by gross developmental delay. We likewise observed
no defects in other structures, including the heart and the swim bladder.
To investigate the mechanism of the head size defects, we examined the developing brain of
both macro-and microcephalic embryos. In situ hybridization with an antisense kctd13 probe
showed this transcript to be expressed strongly in the developing brain. At 24 hpf, kctd13 is
strongly expressed in the anterior forebrain (arrowheads, suppl. Fig. 3a, f), the midbrain, and
the hindbrain. In later stages, kctd13 is expressed predominantly in the telencephalon, the
diencephalon, and the retina (suppl. Fig. 3b-e). Staining both phenotype classes with
terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) showed a
significant increase in apoptosis exclusively in the microcephalic embryos. At the same
time, phospho-histone H3 antibody staining revealed an increase in proliferating cells in the
brain of kctd13 morphants and a reciprocal decrease of proliferating cells in overexpressant
embryos (Fig. 2 c, d). Detailed analysis of transverse sections from embryos injected with
either MO or KCTD13 mRNA confirmed that the observed phenotypes are likely driven by
changes in the number of cells in the developing brain, since the architecture and cell
content of the Meckel and palatoquadrate pharyngeal cartilages were normal, as was the
overall cell content and architecture of the retina (Fig 3a–f). Counting of cell nuclei at 4.5
dpf, when the anatomical measurements were made, showed significant reciprocal changes
in the total number of cells in each of the telencephalon, diencephalon, and mesencephalon
(Fig 3k). Further, counting of HuC/D-positive cells (a marker for post-mitotic neurons) in
the telencephalon recapitulated the differences seen in total cell count but showed no
difference in cell circumference (Fig. 3l; Suppl. Fig. 4), indicating that the changes in
overall cell numbers and ultimate changes in head size are largely driven by changes in the
numbers of mature neurons. These data, collected at 4.5 dpf, predict that the onset of the
neuroanatomical defects would precede the manifestation of anatomical micro- or
macrocephalic phenotypes. To test this hypothesis, we stained all three classes of embryos
with HuC/D and acetylated tubulin at 2 dpf, at which time the head size of kctd13 MOs and
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toverexpressants is indistinguishable from uninjected controls. We observed stark differences
in the density and distribution of neurons, particularly in the forebrain, with concomitant
loss of organization and bilateral symmetry (Fig. 3m) as well as aberrant distribution of
axonal tracks (Fig. 3n).
Although the zebrafish brain bears many similarities in terms of developmental
programming with the mammalian brain, we sought to test whether our findings might be
relevant to cortical development in a mammalian system. Data mining of the Gene
Expression Nervous System Atlas (GENSAT; www.gensat.org) and the Allen brain atlas
(www.brain-map.org) revealed that human and mouse KCTD13 is expressed throughout
development in neurons residing in the cortex, striatum, olfactory tubercle, and
hippocampus. We therefore designed shRNAs against murine Kctd13 and tested their
efficiency in a cultured mouse neuroblastoma cell line (Neuro-2A). One shRNA, which,
similar to the kctd13 MO, downregulated the expression of endogenous message by ~70%
(Suppl. Fig. 5), was then co-transfected with a GFP-expressing plasmid into Neuro-2A cells.
Two days after transfection, cells were pulsed with 5-bromo-2'-deoxyuridine (BrdU) and
analyzed for the effects of Kctd13 knockdown on cellular proliferation. Similar to the
proliferation data using zebrafish morphants, depletion of Kctd13 resulted in a 34% increase
(p<0.01) in BrdU/GFP labeled cells (Fig 4a). We next injected the Kctd13 shRNA and GFP-
expressing plasmid into the ventricular space of wild-type C57BL/6 embryos at embryonic
day 13.5 (E13.5) and injected BrdU into pregnant dams two hours before collection of
electroporated embryos at E15.5. Knockdown of Kctd13 resulted in a two-fold increase in
BrdU/GFP labeling within the ventricular zone (p<0.001; Fig. 4b), suggesting that Kctd13 is
required to maintain the proliferative status of cortical progenitors in vivo.
The combination of our zebrafish and mouse data suggests that KCTD13 is a major driver of
the head size phenotypes associated with the 16p11.2 CNV through the regulation of early
neurogenesis. Our data do not exclude the possibility that other loci also have an
independent contribution to the 16pdel/dup anatomical phenotypes and cannot inform
directly the question whether all of the observed pathology in 16p11.2del/dup patients is
driven by dosage changes in KCTD13. However, we were able to ask whether dosage
changes of other loci inside the CNV might also be relevant to the head size phenotypes
established by KCTD13. Specifically, we performed pairwise overexpressions of KCTD13
with all other 28 transcripts in the region and asked whether we could observe changes in
the penetrance (percentile of microcephalic zebrafish in a clutch) or the expressivity
(percentile changes in mean head size) of the KCTD13-established phenotype. We observed
no changes in penetrance. However, pairwise expression with two other transcripts, MAPK3
and MVP increased significantly the expressivity of the phenotype from 18% for KCTD13
alone to 24% and 22% respectively (Suppl. Fig 6,Suppl. Table 2), predicting that del or dup
patients might have a more severe phenotype that individuals with heterozygous loss of
function at KCTD13 alone.
Finally, we turned our attention to the question of whether loss of KCDT13 might be
sufficient in humans to cause some of the commonly observed phenotypes associated with
the 16p11.2del. During our analyses, a submicroscopic ~118 kb deletion in 16p11.2 that
segregated with ASD and other neurodevelopmental abnormalities was discovered in a
single three-generation pedigree22. This deletion encompasses five genes, MVP, CDIPT1,
SEZ6L2, ASPHD1 and KCTD13, in agreement with our hypothesis that haploinsufficiency
at KCTD13 might contribute to 16p11.2 phenotypes. We performed multiplex ligation-
dependent probe amplification (MLPA; Suppl. Table 3) of this restricted region in 518
subjects that met diagnostic criteria for autism or ASD (Autism Diagnostic Observational
Schedule, ADOS10), finding full-segment deletions in eight independent ASD subjects
(1.54%; six deletion, two duplication), compared to just five such events from 8,328 controls
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t(0.006%)23. We also observed the deletion of a single probe spanning exon 4 of KCTD13 in
one proband with a narrow diagnosis of autism (Suppl. Fig. 7; Suppl. Table 3). The MLPA
assay was replicated in the proband and the deletion was confirmed further by qPCR on two
independently obtained DNA samples (Suppl. Fig. 7). Identical MLPA analyses, as well as
confirmation of paternity by genotyping, were performed in both biological parents,
revealing that the deletion arose de novo and was restricted to the KCTD13 coding region,
maximally 9 kb and including exons 3, 4, and 5 (Suppl. Fig. 7). However, in an extensive
effort to precisely localize the breakpoints by custom tiled array comparative genomic
hybridization (aCGH) of the entire 16p11.2 region we discovered the rearrangement to be
significantly more complicated. We discovered an additional, atypical ~360 kb deletion
distal to the classic 16p11.2 region that was inherited from an asymptomatic mother. The
deletion was confirmed by an independent Agilent 24 M feature aCGH, however the precise
breakpoints could not be definitely localized as the rearrangement is mediated by a highly
complex genomic region of segmental duplication24. The apparent complexity of these co-
occurring events, including both inherited and de novo rearrangements, impacts multiple
loci in addition to KCTD13, suggesting this phenotype cannot be attributed solely to the
KCTD13 alteration.
In aggregate, our data support a major contributory role for KCDT13 in the 16p11.2 CNV
through four lines of evidence: a) the in vivo overexpression screen yielded microcephaly in
1/29 genes; b) the reciprocal suppression of this locus mirrored the corresponding human
16p11.2del phenotypes; c) functional analyses established a neurogenic defect that was
consistent across species; and d) KCTD13 lies in the putative critical region of ~118 kb
region delineated in one family with ASD independent from our study, and, here, we found
a complex rearrangement that includes de novo alteration affecting a portion of the coding
region in a patient with a narrow diagnosis of autism.
Given that the design of our screen relies on a heterologous system of expression, we do not
exclude the possibility that other genes in the 16p11.2 CNV might also be relevant to human
pathology but did not trigger phenotypes in zebrafish embryos, especially the five transcripts
not present in the zebrafish genome. Moreover, we do not know whether dosage imbalance
of KCTD13 might regulate other phenotypes commonly associated with the 16p11.2 CNV,
such as obesity and epilepsy4–6. However, it is reasonable to speculate that the
neurodevelopmental changes observed upon KCTD13 perturbation could contribute to those
phenotypes. We note that loss of function mutations of another member of this family,
KCTD7 cause progressive myoclonic epilepsy25, while variants in KCTD15 have been
associated with obesity26.
KCTD13 encodes the polymerase delta-interacting protein 1 (PDIP1), that interacts with the
Proliferating Cell Nuclear Antigen (PCNA)27 and thus might have a role in the regulation of
cell cycle during neurogenesis. Our studies might also inform disease architecture and
whether changes in neuronal populations can account for brain overgrowth phenotypes28.
Although our data suggest that disregulated KCTD13 levels are sufficient to establish
neuroanatomical defects, its genetic interaction with at least one more locus leads us to
speculate that the point mutation event that would phenocopy the 16p11.2del might not be
represented by single loss of function alleles at KCTD13, but at cis alleles in KCTD13 and
MAPK3, as well as MVP, or combined haploinsufficiency of all three. Testing this
hypothesis with sufficient statistical power will require the analysis of large cohorts.
Similar to our study, the 16p11.2 CNV has been modeled in mice by chromosomal
engineering, where neuroanatomical volumetric changes in regions analogous to our
observations (e.g the forebrain and midbrain) have been noted29. Our approach is likely to
be particularly useful in resolving a rapidly growing number of genomic regions implicated
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tin a range of human genomic disorder phenotypes30 that a) are involved in both deletion and
duplication syndromes such as 7q11.23 CNV10; and b) have mirroring anatomical
phenotypes that can be assayed in a physiologically-relevant developmentalsystem (such as
1q21.1, and 3q39 CNVs1). Such analyses will expedite the identification of major dosage-
sensitive loci and accelerate our biological understanding of CNVs that, together, account
for a significant fraction of the mutational burden of neurodevelopmental disorders1,11.
Methods Summary
Morpholino, in vivo analysis of gene expression and embryo manipulations
Splice-blocking morpholino (MO) against Kctd13 was designed and obtained from Gene
Tools, LLC (5’-TCTAAGGGTACACGCCTGACCTGTA-3’). Control MO was the
scrambled nucleotide sequence from Gene Tools, LLC (5'-
CCTCTTACCTCAGTTACAATTTATA- 3'). MO injection, RNA rescue and
overexpression experiments are performed using standard protocol.
Immunostaining and TUNEL assay
Embryos were fixed in 4% PFA or in Dent’s fixative (80% methanol, 20% DMSO)
overnight at 4°C. Embryos were incubated in the first antibody solution, 1:750 anti-histone
H3 (ser10)-R, (sc-8656-R, Santa Cruz), 1:1000 anti-HuC/D (A21271, Invitrogen), 1:1000
anti-acetylated tubulin (T7451, Sigma-Aldrich). Apoptotic cell death in zebrafish whole-
mounts was detected according to a modification of the ApopTag rhodamine In Situ
Apoptosis Detection kit (Chemicon,Temecula, CA) protocol. Embryos for cryosectioning
were fixed, incubated in PBS-sucrose 30%, embedded in Tissue-Tek O.C.T. Embedding
Compound (Sakura Finetek) and sectioned at 7 µm.
In utero microinjection
E13.5 embryos were injected with either control or Kctd13 shRNA constructs and a GFP-
expressing vector. Forty-eight hours after electroporation, BrdU (100 mg/kg) was injected
intraperitoneally into the pregnant dams and embryos were harvested 2 hours later. Embryo
brains were processed and sectioned (20 µm) before staining with a BrdU antibody
(Accurate).
Short arm of chromosome 16 custom array-CGH
DNA samples from the proband and both parents were labelled with Cy3 and cohybridized
with Cy5-labelled control DNA from an unaffected CEPH individual obtained from Coriell
(GM10851) to custom-made Nimblegen arrays. DNA labelling, hybridization and washing
were performed according to Nimblegen protocols. Scanning was performed using an
Agilent G2565BA Microarray Scanner. Image processing, quality control and data
extraction were performed using the Nimblescan software v.2.5.
Methods
Morpholino, in vivo analysis of gene expression and embryo manipulations
Splice-blocking morpholino (MO) against Kctd13 was designed and obtained from Gene
Tools, LLC (TCTAAGGGTACACGCCTGACCTGTA). Control MO was the scrambled
nucleotide sequence from Gene Tools, LLC (5'-CCTCTTACCTCAGTTACAATTTATA-
3'). We injected 1nl of diluted MO (6, 8, 10 ng) and/or RNA (50, 75, 100 pg) into wildtype
zebrafish embryos at the 1-to 2-cell stage. Injected embryos were scored at 4.25 dpf and
classified into two groups, i.e. normal and mutant, on the basis of the relative head size
compared with age-matched controls from the same clutch. For RNA rescue and
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toverexpression experiments, the human wild type mRNAs was cloned into the pCS2 vector
and transcribed in vitro using the SP6 Message Machine kit (Ambion). All the experiments
were repeated three times and we ran a t-test to determine the significance of the morphant
phenotype. Whole-mount in situ hybridizations were carried out using antisense probes for
kctd13 made from clone (Openbiosystems) and following standard protocols. Further
processing included clearing in methyl salicylate and flat mounting were performed using
standard protocol.
Whole-Mount TUNEL assay
Apoptotic cell death in zebrafish whole-mounts was detected according to a modification of
the ApopTag rhodamine In Situ Apoptosis Detection kit (Chemicon,Temecula, CA)
protocol. Embryos were fixed in 4% paraformaldehyde (PFA) at 4°C overnight and store in
100% methanol at −20°C. After rehydratation in PBS, embryos were permeabilized by a 5
minutes digestion with proteinase K (10µg/ml) in PBS at room temperature. After two
washes in sterile water for 3 minutes each, embryos were postfixed with 4% PFA for 20
minutes, room temperature and then with prechilled ethanol:acetic acid (2:1) for 10 minutes
at -20°C. Embryos were washed in PBS-T (PBS 1X, 0.1% Tween-20) for 5 minutes, 3 times
at room temperature. The incubation in the equilibration buffer and the further steps were
followed according to the standard protocol suggested by the manufacturer. TUNEL staining
was quantified by counting positive cells in defined regions of the head and with ImageJ
software.
Zebrafish whole-mount and section immunostaining
Embryos were fixed in 4% PFA overnight and stored in 100% methanol at −20°C. For
acetylated tubulin staining embryos were fixed in Dent’s fixative (80% methanol, 20%
DMSO) overnight at 4°C. The embryos were permeabilized with proteinase K followed by
post-fixation with 4% PFA, washed in PBSTX (PBS+0.5% Triton X-100). After rehydration
in PBS, PFA-fixed embryos were washed in IF buffer (0.1% Tween-20, 1% BSA in PBS
1X) for 10 minutes at room temperature. The embryos were incubated in the blocking buffer
(10% FBS, 1% BSA in PBS1X) for 1hr at room temperature. After two washes in IF Buffer
for 10 minutes each, embryos were incubated in the first antibody solution, 1:750 anti-
histone H3 (ser10)-R, (sc-8656-R, Santa Cruz), 1:1000 anti-HuC/D (A21271, Invitrogen),
1:1000 anti-acetylated tubulin (T7451, Sigma-Aldrich) in blocking solution, overnight at
4°C. After two washes in IF Buffer for 10 minutes each, embryos were incubated in the
secondary antibody solution, 1:1000 Alexa Fluor donkey antirabbit IgG and Alexa Fluor
goat anti-mouse IgG (A21207, A11001, Invitrogen) in blocking solution, for 1hr at room
temperature. Staining was quantified by counting positive cells in defined regions of the
head and with ImageJ software. Embryos for cryosectioning were fixed in 4% PFA
overnight at 4°C, washed twice in phosphate-buffered saline (PBS) and incubated in PBS-
sucrose 30% at 4°C overnight. Embryos were embedded in Tissue-Tek O.C.T. Embedding
Compound (Sakura Finetek). Sections were cut at 7 µm.
Cell Proliferation assay
Neuro-2A cells were seeded in 2 well chamber slides and transfected with control and
Kctd13 shRNA constructs and a GFP expressing plasmid. Two days after transfection, cells
were pulsed with 10 µM BrdU, fixed and stained with a BrdU antibody (Accurate).
In utero microinjection
E13.5 embryos were injected with either control or Kctd13 shRNA constructs and a GFP-
expressing vector. Forty-eight hours after electroporation, BrdU (100 mg/kg) was injected
intraperitoneally into the pregnant dams and embryos were harvested 2 hours later. Embryo
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tbrains were processed and sectioned (20 µm) before staining with a BrdU antibody
(Accurate).
Multiplex ligation-dependent probe amplification (MLPA)
A custom assay with 29 probes was designed to capture candidate genes in the 118 kb
16p11.2 putative critical region (23 probes to the targeted genes KCTD13, MVP, and
CDIPT; 2 probes to 16p11.2 microdeletion region genes not within the putative critical
region, TAOK2 and TBX6; 4 probes to control genes outside of the region). The assay was
performed with 100–150 ng genomic DNA (quantified byPico-Green (Quant-iT,
Invitrogen)) according to manufacturer’s instructions. All samples were performed in
triplicate. Amplification products from ligated probes were run on an ABI 3730xl DNA
Analyzer using Genescan-Rox500 size standards (Applied Biosystems Inc). MLPA peak
plots were visualized and analyzed using GeneMarker Software Trial Version 1.91
(SoftGenetics LLC). Peak height and area were compared between control individuals and
ASD samples. Values between 0.75 and 1.3 were considered normal.
Real-time Quantitative PCR
Each quantitative real-time PCR was performed in a 96-well plate using 2×LightCycler 480
SYBR Green I Master mix (Roche Applied Science) according to manufacturer's
instructions. All products were cycled at: 95°C for 2 min followed by 45–55 cycles of 95°C
for 15 s and 60°C for 1 min. Melt temperature analysis was performed at the end of each run
to confirm PCR specificity. Relative copy number was determined between the proband
(AC02-1467-01) and three control subjects for probes designed within exon 4 of KCTD13
and control probes localized outside of the 16p11.2 microdeletion region.
Short arm of chromosome 16 custom array-CGH
DNA samples from the proband and both parents were labelled with Cy3 and cohybridized
with Cy5-labelled control DNA from an unaffected CEPH individual obtained from Coriell
(GM10851) to custom-made Nimblegen arrays. These arrays contained 71,000 probes
spread across the short arm of chromosome 16 from 22.0 to 32.7 Mb (at a median space of
45 bp between 27.5 and 31.0 Mb) and 1,000 control probes situated in invariable region of
the X chromosome. DNA labelling, hybridization and washing were performed according to
Nimblegen protocols. Scanning was performed using an Agilent G2565BA Microarray
Scanner. Image processing, quality control and data extraction were performed using the
Nimblescan software v.2.5.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Systematic analysis of 16p11.2 del/dup genes in vivo induces defects in head size
(a) Schematic of chromosome 16, zoomed in the 16p11.2 CNV, showing gene content (not
to scale) above the black line. (b) Plot of head size measurements (in µm) of human mRNA
overexpression combinations measured across ~50 embryos/injection cocktail. In all but one
injection, both controls and human overexpressed genes result in indistinguishable median
head size, with minimal variance. By contrast, embryos injected with the KCTD13/CDIPT
mRNAs cocktail show consistent and significant reduction of head size.
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tFigure 2. KCTD13 dosage changes lead to head size, proliferation and apoptosis defects
(a) From top to bottom, dorsal (left) and lateral (right) views of representative embryos
injected with Kctd13 MO, control, or KCTD13 mRNA. (b) Graph of the ratio between
control and injected embryos head size measures at 4.5 dpf (n=45). (c) Phospho-histone H3
(top panel) and TUNEL (bottom panel) staining for proliferating or apoptotic cells in
zebrafish brain at 2 dpf and 3 dpf respectively. From left to right are representative examples
of MO-, control- and mRNA-injected embryos. (d) Graph of phospho-histone H3 and
TUNEL quantifications from 20 MO-, control and mRNA-injected embryos. Data from
three independent experiments are represented as mean ± s.d. *** p<0.00001; two-tailed t-
test comparisons between control and either MO-and mRNA-injected embryos.
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tFigure 3. KCTD13 dosage changes lead to neuroanatomical defects
DAPI staining on transverse sections of the telencephalon (a, b, c), the diencephalon (d, e, f),
and the mesencephalon (g, h, i) of embryos injected with kctd13 MO, control or KCTD13
mRNA at 4.5 dpf. (j) The planes of section are illustrated with red lines on dorsal views of
kctd13 MO-, control-, and KCTD13 mRNA-injected embryos (left to right). Higher
magnifications of the telencephalon (a–c) and the diencephalon (d–f) are in (a’–f’). The
Meckel pharyngeal cartilage (a–c) and the palatoquadrate pharyngeal cartilage (d–f) are in
insets. Scale bar, 100µm. (k) Bar graph of the total number of nuclei for the three classes of
embryos in the telencephalon, diencephalon and mesencephalon at 4.5 dpf (3 adjacent
sections, n=4). (l) Bar graph of the number of HuC/D positive cells in the telencephalon for
kctd13 MO-, control- and KCTD13 mRNA-injected embryos at 4.5 dpf (3 adjacent sections,
n=4). (m) Ventral and (n) dorsal views of kctd13 MO-, control-, and KCTD13 mRNA-
injected embryos at 2 dpf (left to right). Data are represented as mean ± s.d. * p<0.01; two-
tailed t-test comparisons between control and either MO- and mRNA-injected embryos.
Golzio et al. Page 13
Nature. Author manuscript; available in PMC 2012 November 16.
$
w
a
t
e
r
m
a
r
k
-
t
e
x
t
$
w
a
t
e
r
m
a
r
k
-
t
e
x
t
$
w
a
t
e
r
m
a
r
k
-
t
e
x
tFigure 4. Kctd13 regulates mammalian cell proliferation in vitro and in vivo
(a) Knockdown of Kctd13 in Neuro-2a cells results in an increase in the number of BrdU+/
GFP+ cells relative to control cells. Error bars represent the standard error from two
independent experiments.
(b) Analysis of E15.5 mouse cortices injected with either Kctd13 or control shRNA reveal a
similar increase in BrdU+/GFP+ cells in knockdown tissue (n=3, error bars represent the
standard error). ** p<0.01; ***p<0.001.
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